Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study

• Sponsor: Hospices Civils de Lyon (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04009733
• Collaborator: (none)
• Enrollment: 100
• Location: 1
• Arms: 3
• Anticipated Duration (Months): 42.9
• Patients Per Site Per Month: 2.3

Study Details

Study Description

Brief Summary

Osteogenesis Imperfecta (OI) is a heterogeneous group of rare connective tissue hereditary diseases responsible for fragility and bone deformity. OI is caused by an autosomal dominant mutation of COL1A1 or COL1A2, encoding α1 and α2 of the collagen, regardless of their phenotypic severity (1 to 5 OI type).

This observation suggests the existence of a undetermined mechanism that may be found in epigenetic regulation, including particularly micro Ribonucleic Acids (miRs).

Indeed, these small non-coding miRs are involved in the regulation of major steps of cellular processes in different pathologies, especially in bone disease.

Currently, no study can provide a satisfactory answer.

This is an etiologic study to reveal the correlation between micro-RNAs (miR) expression and the type I or III of the Osteogenesis Imperfecta (OI).

The aim of this study is therefore to identify miRs significantly associated with the severity of OI.

Condition or Disease	Intervention/Treatment	Phase
Osteogenesis Imperfecta	Biological: Blood sample; Biological: Blood sample	N/A

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 100 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
• Actual Study Start Date: Oct 3, 2019
• Anticipated Primary Completion Date: May 2, 2023
• Anticipated Study Completion Date: May 2, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Osteogenesis imperfecta type 1 Patients with OI type 1	Biological: Blood sample; A study specific blood sample will be collected.
Experimental: Osteogenesis imperfecta type 3 Patients with OI type 3	Biological: Blood sample; A study specific blood sample will be collected.
Active Comparator: Control population The control population corresponds to a pre-existing serum collection of osteoarthritis cohorts (OFELY and MODAM for women, STRAMBO for men).	Biological: Blood sample; Pre-collected serum of cohort OFELY and MODAM for women, STRAMBO for men will be used for the study.

Outcome Measures

Primary Outcome Measures

1. micro Ribonucleic Acids (miRs) expression in serum of the patients Osteogenesis imperfecta (OI) type I or III versus control population [up to 1 month (after inclusion)]

   Identification of specific miRs expressed in the serum of OI patients using NGS (Next Generation Sequencing).

Secondary Outcome Measures

1. Nature of micro Ribonucleic Acids (miRs) identified by Next-Gen Sequencing (NGS ) [Up to 1 month (after inclusion)]

   Compare the nature of the miRs identified by NGS (Next Generation Sequencing) in serum between the 3 groups of subjects: type 1 Osteogenesis Imperfecta (OI), type 3 OI and controls (controls are patients with osteoarthritis).

2. Level of expression of micro Ribonucleic Acids (miRs) identified by Next-Gen Sequencing (NGS ) [Up to 1 month (after inclusion)]

   The objective is to validate expression of miRs identified by NGS (Next Generation Sequencing) in blood samples of patients from 3 groups: an Osteogenesis imperfecta (OI) type 1 cohort and an OI type 3 cohort, recruited for the study, and a pre-existing group of control patients (issued from cohorts OFELY and MODAM for women, STRAMBO for men). Expression of the significant miRs identified by NGS will be measured by Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) and then these results will be compared with same analysis on blood samples of control patients.

3. Presence of fracture [Up to 1 month (after inclusion)]

   Severity of OI will be evaluated using radiological data (fracture) extracted from patients' medical records. Association between expression of miRs in patients with OI with the severity of the disease will be studied by statistical analysis.

4. Presence of biochemical markers of bone turnover in blood [Up to 1 month (after inclusion)]

   Severity of OI will be evaluated using biological data (biochemical markers of bone turnover) extracted from patients' medical records. Association between expression of miRs in patients with OI with the severity of the disease will be studied by statistical analysis.

5. Bone pain [Up to 1 month (after inclusion)]

   Severity of OI will be evaluated using clinical data (bone pain mesured on Visual Analogue Scale) extracted from patients' medical records. Association between expression of miRs in patients with OI with the severity of the disease will be studied by statistical analysis.

6. Quality of life [Up to 1 month (after inclusion)]

   Investigators will use a specific questionnaire completed by a rheumatologist at inclusion to obtain more information about a patient's lifestyle. The higher the score the more severe the disease impact and vice versa. Association between expression of miRs in patients with OI with the severity of the disease will be studied by statistical analysis.

7. Assessment of environmental factors [Up to 1 month (after inclusion)]

   The investigating team will use information extracted from patients' medical records to obtain environmental information, which includes using a specific questionnaire completed by a rheumatologist with patients at inclusion. Association between expression of miRs in patients with OI with the environmental data will be studied by statistics analysis.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

Control population:

• Male or female

• 18 years old and over

• Be part of cohorts STRAMBO, OFELY or MODAM

Patients with OI:

• Male or female ≥18 years old

• Have COL1A1 or COL1A2 mutation

• Have a diagnosis of type 1 or 3 from Silence classification made by a rheumatologist expert in bone pathologies

Exclusion Criteria:

• Refusal to participate in the study

• Have received glucocorticoid treatment for more than 3 months

• Have received anti-osteoporotic treatment for less than 1 year ago

• Have Chronic inflammatory rheumatism

• Have an uncontrolled hypo/hyper thyroidism ou hypo/hyper parathyroidism

• Have cancer or bone metastases (current or in the past two years)

• Have benign bone tumors or Paget's disease

• Have malabsorptive disease (Celiac disease, Whipple's disease, intestinal bypass, short bowel syndrome) and inflammatory bowel disease

• Pregnant or lactating women

• Have psychiatric disorders seriously hindering understanding

• Have difficulties in oral understanding of French language

• Not a beneficiary of french social security

• Patients protected by law

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hôpital Edouard Herriot	Lyon		France	69003

Sponsors and Collaborators

• Hospices Civils de Lyon

Investigators

• Principal Investigator: Roland CHAPURLAT, PhD, Hospices Civils de Lyon

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hospices Civils de Lyon
• ClinicalTrials.gov Identifier: NCT04009733
• Other Study ID Numbers: 69HCL19_0021; 2019-A00521-56
• First Posted: Jul 5, 2019
• Last Update Posted: Jan 19, 2022
• Last Verified: Jan 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Hospices Civils de Lyon: Osteogenesis imperfecta; micro Ribonucleic acids; epigenetics
• Additional relevant MeSH terms: Osteogenesis Imperfecta

Study Results

No Results Posted as of Jan 19, 2022